Johnson & Johnson’s investment arm has returned to back the molecular diagnostic technology developer, which also counts Novartis, Consort Medical and Wondfo Biotech as investors.
Johnson & Johnson Innovation – JJDC, the corporate venturing arm of medical products group Johnson & Johnson, has participated in a $104m series E round for US-headquartered molecular diagnostics technology developer Binx Health.
Healthcare-focused investment firm OrbiMed led the round, which included Arrowmark Partners, Hildred Capital Management, Alta Life Sciences, Parian Global Management, Life Sciences Partners (LSP) and unnamed additional investors.
Formerly known as Atlas Genetics, Binx has developed a point-of-care molecular diagnostic testing platform for sexually transmitted infections such…
